NBIX · Neurocrine Biosciences Inc

Back to holdings

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.

Close · 3M

+8.74%

Held by 1 AI ETF

AIVL0.658%

as of Oct 23

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals3

Win rate33% (1/3)

Avg buy return+0.05%

AIVLnow 0.658% of fund5 signals

AIVL · Weight increase · 2d

weight 0.651% → 0.658% (+0.007 pp)·stock down 2.9% in the 30 days before

Oct 23·entry $142.70·now $142.70Fresh

0.00%

since Oct 23

AIVL · Weight increase · 2d

weight 0.632% → 0.655% (+0.024 pp)·stock up 7.8% in the 30 days before

Oct 20·entry $142.00·now $142.70Fresh

+0.49%

since Oct 20

AIVL · Weight decrease · 2d

weight 0.668% → 0.632% (-0.036 pp)

Oct 13·entry $135.13·now $142.70

+5.60%

since Oct 13

AIVL · Weight decrease · 2d

weight 0.689% → 0.668% (-0.021 pp)

Oct 8·entry $141.25·now $142.70

+1.03%

since Oct 8

AIVL · New entry · 1d

weight 0 → 0.694% (new)

Oct 2·entry $143.18·now $142.70Fresh

-0.34%

since Oct 2

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.